ENDRA Life Sciences Inc. (NDRA) - Dilution Analysis

8-K filing: ENDRA Life Sciences Inc. entered into a securities purchase agreement to issue 578,387 shares of common stock and warrants in a private placement for expected gross proceeds of approximately $3.8 million. ($3.8M proceeds)

10-Q filing | 1.2M shares outstanding

10-K filing | 1.2M shares outstanding

8-K filing: ENDRA Life Sciences Inc. closed a private placement offering of 744,340 shares of common stock and warrants to purchase up to 1,488,680 shares of common stock for gross proceeds of approximately $4.9 million on October 15, 2025. ($4.9M proceeds)

10-Q filing | 1.2M shares outstanding

S-3 filing: This prospectus relates to the possible resale of common stock by selling stockholders.

8-K filing: ENDRA Life Sciences Inc. entered into a securities purchase agreement to sell 744,340 shares of common stock and warrants to purchase up to 1,488,680 shares of common stock in a private placement offering, with gross proceeds of approximately $4.9 million, along with issuing warrants to Arca for 400,000 shares and warrants to the placement agent for 44,660 shares. ($4.9M proceeds)

10-Q filing | 0.5M shares outstanding

S-1/A filing: The company is offering 15,700,000 shares of common stock and pre-funded warrants to purchase up to 15,700,000 shares of common stock, as well as underwriter warrants to purchase up to 628,000 shares of common stock.

S-1/A filing: The company is offering 15,700,000 shares of common stock and pre-funded warrants to purchase up to an aggregate of 15,700,000 shares of common stock.

S-1 filing: The company is offering 15,700,000 shares of common stock and pre-funded warrants to purchase up to an aggregate of 15,700,000 shares of common stock.

10-Q filing | 0.5M shares outstanding

10-K filing | 0.0M shares outstanding

8-K filing: Stock split 1-for-35 | Outstanding: 20,000,000 → 571,400

8-K filing: Stock split 1-for-50 | Outstanding: 72,439,526 → 20,000,000

10-Q filing | 72.4M shares outstanding

8-K filing: ENDRA Life Sciences, Inc. closed an offering of 6,107,691 shares of common stock and pre-funded warrants to purchase up to 55,430,770 shares of common stock, along with warrants to purchase up to 123,076,922 shares of common stock, for gross proceeds of approximately $8 million. ($0.0M proceeds)

S-1/A filing: The filing is for an offering of common stock together with warrants, including pre-funded warrants, Series A warrants, Series B warrants and Placement Agent warrants. A placement agent has been engaged.

10-Q filing | 10.9M shares outstanding

S-1/A filing: The company is offering shares of common stock together with warrants, pre-funded warrants together with common warrants, and placement agent warrants.

S-1 filing: This S-1 filing details a firm commitment public offering of common stock, along with Series A and B warrants, and pre-funded warrants to purchase common stock. The common stock and warrants are sold in a fixed combination and are immediately separable.

S-3/A filing: ENDRA Life Sciences Inc. is offering common stock, preferred stock, debt securities, warrants and units for sale from time to time in one or more offerings on terms to be determined at the time of sale, with an aggregate offering amount of $50,000,000.

10-K filing | 10.4M shares outstanding

S-3 filing: ENDRA Life Sciences Inc. files an S-3 to offer common stock, preferred stock, and debt securities for a total proposed amount of $50,000,000.

10-Q filing | 8.4M shares outstanding

10-Q filing | 7.5M shares outstanding

10-Q filing | 3.2M shares outstanding

8-K filing: ENDRA Life Sciences Inc. completed an offering of 3,750,000 shares of common stock and warrants to purchase up to 1,875,000 shares, with the underwriter exercising the over-allotment option to purchase an additional 562,500 shares and warrants to purchase 281,250 shares, resulting in net proceeds of approximately $4.5 million. ($4.5M proceeds)

S-1/A filing: The company is offering 3,000,000 shares of common stock and warrants to purchase up to 1,500,000 shares of common stock.

S-1/A filing: The company is offering 3,000,000 shares of common stock and warrants to purchase up to 1,500,000 shares of common stock.

10-K filing | 3.2M shares outstanding

10-Q filing | 63.2M shares outstanding

10-Q filing | 63.2M shares outstanding

10-Q filing | 44.6M shares outstanding

10-K filing | 42.6M shares outstanding

10-Q filing | 42.2M shares outstanding

10-Q filing | 41.9M shares outstanding

10-Q filing | 41.7M shares outstanding

10-K filing | 8.4M shares outstanding

S-3 filing: ENDRA Life Sciences Inc. files an S-3 registration statement for the potential sale of common stock, preferred stock, and debt securities, with a total proposed amount of $50,000,000.

10-Q filing | 8.4M shares outstanding

10-Q filing | 8.4M shares outstanding

10-Q filing | 14.5M shares outstanding

10-K filing | 7.4M shares outstanding

S-3/A filing: This S-3/A filing details the offering of common stock by selling stockholders.

S-3 filing: This is an S-3 filing that details the terms of Series A Warrants and Placement Agent Warrants, Series B Preferred Stock, Series B Warrants and Series B Placement Agent Warrants.